HUP becomes first in region to implant a HeartMate II Left Ventricular Assist System into a patient

July 19, 2005

(Philadelphia, PA) - Cardiothoracic surgeons at the Hospital of the University of Pennsylvania (HUP) are helping to pave the way for new implantable pump devices to treat end-stage heart disease. As part of a nationwide clinical trial, HUP cardiothoracic surgeons have became the first in the region to implant a HeartMate II Left Ventricular Assist System into a patient for ongoing, permanent support for late-stage heart failure, otherwise known as Destination Therapy. The adult male is now recovering after the procedure done on July 14th.

"Before this procedure, this patient was dying of end-stage heart failure. He reported that his quality-of-life was seriously diminished and his clinical condition suggested that he had only a few more weeks to live," said Mike Acker, MD, Chief of Cardiothoracic Surgery at the Hospital of the University of Pennsylvania, "What makes this particular device so unique is that rather than mimicking the actual pumping motion of the heart, it works to put out a continuous flow of blood. And it's only about the size of your thumb. It will require less surgical trauma than other current devices and it can be used in smaller people like women and children."

The HeartMate II device is powered by a rotary pumping mechanism, with one moving part, and weighs only about 14 ounces. It is much smaller and quieter than other currently approved devices. The device is implanted alongside a patient's heart and takes over the job of moving along the blood of the weakened heart's left ventricle. An external controller regulates pump speed and a power cable connects the device to a small monitor and power base unit. It's about 1.8 inches in diameter and 3.2 inches long. It pumps blood from the heart throughout the body at up to 10 liters per minute, the full output of a healthy heart. It's designed for reliable long-term support to improve outcomes and quality of life.

Rohinton Morris, MD, Surgical Director of the Heart Transplant Program at the Hospital of the University of Pennsylvania added, "The axial flow device is a significant addition to the various surgical methods of treating end-stage heart failure. It is a major advance in treatment, and holds high promise for the future."

Thoratec, the maker of the HeartMate II Left Ventricular Assist System, says it's designed to address the need for smaller, long lasting devices in Destination Therapy for patients requiring long-term cardiac support. The clinical study is being held at 27 centers across the nation, including HUP.
-end-
Editor's Note: Drs. Michael Acker and Rohinton Morris have no financial interest in Thoratec Corporation.

Drs. Acker and Morris are both available for interviews. Please schedule through Susanne Hartman at 215-349-5964.

Finally, you can go to: www.thoratec.com/news/image_catalogue.htm and download the three diagrams of the HeartMate II LVAS for use in your coverage. Please use this wording in the caption: "Reprinted with permission from Thoratec Corporation."

PENN Medicine is a $2.7 billion enterprise dedicated to the related missions of medical education, biomedical research, and high-quality patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System.

Penn's School of Medicine is ranked #2 in the nation for receipt of NIH research funds; and ranked #4 in the nation in U.S. News & World Report's most recent ranking of top research-oriented medical schools. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.

The University of Pennsylvania Health System includes three owned hospitals [Hospital of the University of Pennsylvania, which is consistently ranked one of the nation's few "Honor Roll" hospitals by U.S. News & World Report; Pennsylvania Hospital, the nation's first hospital; and Penn Presbyterian Medical Center]; a faculty practice plan; a primary-care provider network; two multispecialty satellite facilities; and home care and hospice.

University of Pennsylvania School of Medicine

Related Heart Articles from Brightsurf:

New 'atlas' of human heart cells first step toward precision treatments for heart disease
Scientists have for the first time documented all of the different cell types and genes expressed in the healthy human heart, in research published in the journal Nature.

Highly detailed map of the human heart could guide personalized heart treatments
Scientists have created a detailed cellular and molecular map of the healthy human heart to understand how this vital organ functions and to shed light on what goes awry in cardiovascular disease.

Highly detailed map of human heart could guide personalised heart treatments
Scientists have created the most detailed cellular and molecular map of the healthy human heart ever, to understand how the heart functions, and illuminate what goes wrong in cardiovascular disease.

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Molecular imaging identifies link between heart and kidney inflammation after heart attack
Whole body positron emission tomography (PET) has, for the first time, illustrated the existence of inter-organ communication between the heart and kidneys via the immune system following acute myocardial infarction.

New heart valve could transform open heart surgery for millions of patients globally
A new polymeric heart valve with a life span potentially longer than current artificial valves that would also prevent the need for the millions of patients with diseased heart valves to require life-long blood thinning tablets has been developed by scientists at the universities of Bristol and Cambridge.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Digital heart model will help predict future heart health, new study finds
In recent times, researchers have increasing found that the power of computers and artificial intelligence is enabling more accurate diagnosis of a patient's current heart health and can provide an accurate projection of future heart health, potential treatments and disease prevention.

Read More: Heart News and Heart Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.